Endo Health to pay $192.7M in gov't settlement

by The Associated Press

Endo Health will pay almost $193 million to resolve claims that it improperly marketed the shingles treatment Lidoderm for unapproved uses like treating lower back pain.

The Malvern, Pennsylvania, drugmaker will pay $171.9 million in civil false claims settlements largely to the U.S. government, with $34.2 million from that total going to 47 states and the District of Columbia. Endo also agreed to pay $20.8 million as part of a deferred prosecution agreement.

U.S. prosecutors said Friday that Endo Health Solutions Inc. marketed the for unapproved uses between 2002 and 2006.

Endo said it was pleased to resolve the issue, and it has programs in place to help it comply with the agreements. The had already set aside $194 million to cover settlement costs.

Doctors can prescribe medicines for any use, but drug makers cannot promote them in any way that is not approved by the U.S. Food and Drug Administration.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Pfizer to pay $491M to resolve drug marketing case (Update)

Jul 30, 2013

The U.S. Justice Department said Tuesday that drugmaker Pfizer Inc. will pay almost $491 million to resolve an investigation into illegal marketing of the organ transplant drug Rapamune by a company Pfizer later acquired.

NJ drugmaker faces civil, criminal fines over drug

Mar 05, 2013

(AP)—A New Jersey-based generic drug maker has agreed to pay $45 million to resolve criminal and civil liability charges for improperly marketing its weight-gain drug to frail seniors.

J&J to pay $2.2B to settle marketing allegations (Update)

Nov 04, 2013

Johnson & Johnson and its subsidiaries have agreed to pay over $2.2 billion to resolve criminal and civil allegations that the company promoted powerful psychiatric drugs for unapproved uses in children, seniors and disabled ...

Recommended for you

Xtoro approved for swimmer's ear

9 hours ago

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

Drug interaction identified for ondansetron, tramadol

10 hours ago

(HealthDay)—In the early postoperative period, ondansetron is associated with increased requirements for tramadol consumption, according to a review and meta-analysis published online Dec. 10 in Anaesthesia.

New system targets germs in donated blood plasma

Dec 17, 2014

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

Judge halts Alzheimer's drug swap until July

Dec 16, 2014

A federal judge has ordered an Irish drug manufacturer to halt its plans to discontinue its widely used Alzheimer's medication, allegedly in an effort to drive patients to a newer patented drug.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.